1. Pink Sheet

Brazil Considers Easier Path For Compulsory Licensing

President Is Unlikely To Sign Off Bill

 
• By Francesca Bruce

A bill amending Brazilian patent law to make compulsory licensing easier has passed the senate but still must be signed off by president Jair Bolsonaro.

BrazilMap_1200x675
Brazilian compulsory licensing bill awaits sign off from president

Proposals to facilitate compulsory licensing in Brazil extend beyond the COVID-19 crisis to other public health emergencies. While industry says the proposals are unnecessary and would damage investment in the sector, public health advocates argue they come as a result of pharma’s failure to engage with voluntary mechanisms to ensure demand for COVID-19 vaccines is met.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.